摘要
目的探讨HAD方案诱导治疗急性髓系白血病临床疗效及不良反应。方法将58例急性髓系白血病患者随机分为2组,治疗组30人,应用HAD方案诱导治疗,对照组28人随机应用DA/HA方案诱导治疗。结果 HAD组诱导化疗完全缓解率(CR)为76.7%,部分缓解率(PR)为13.3%,总有效率为90%,DA/HA方案诱导化疗完全缓解率(CR)为32.1%,部分缓解率(PR)为28.6%,总有效率为60.7%,观察组的缓解率及总有效率明显高于对照组,P<0.05,差异有统计学意义,2组不良反应相当。HAD方案骨髓抑制及粒细胞缺乏严重程度相对DA/HA重一些。结论 HAD方案诱导化疗治疗急性髓系白血病疗效优于DA/HA方案,且毒副作用相当。
Objective Study clinical efficacy and adverse drug reaction of HAD regimen for acute myeloid leukemia. Methods 58 cases of acute myeloid leukemia patients were randomly divided into 2 groups, the treatment group of 30 patients were treated with HAD regimen, 28 cases in the control groups were treated with DA/HA group induction therapy. Results HAD group of induction chemotherapy complete remission （CR） rate was 76.7%, partial remission （PR） rate was 13.3%, the total effective rate was 90%. Complete remission induction chemotherapy of DA/HA regimen （CR） rate was 32.1%, partial remission （PR） rate was 28.6%, the total effective rate was 60.7%, relief and the rate of the observation group was better than that in control group, P〈0.05. The difference was statistically signiifcant, adverse reaction in 2 groups were considerable. The HAD scheme of bone marrow suppression and agranulocytosis severity DA/HA were relatively heavier. Conclusion Take HAD regimen as induction chemotherapy in the treatment of acute myeloid leukemia curative effect is better than the DA/HA scheme, and has considerable side effects.
出处
《中国继续医学教育》
2015年第4期83-83,共1页
China Continuing Medical Education
